Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines

Bergman, 2003, Mechanisms of anticancer drug resistance, Veterinary Clinics of North America. Small Animal Practice, 33, 651, 10.1016/S0195-5616(03)00004-4 Bergman, 1996, Monoclonal antibody C219 immunohistochemistry against P-glycoprotein. Sequential analysis and predictive ability in dogs with lymphoma, Journal of Veterinary Internal Medicine, 10, 354, 10.1111/j.1939-1676.1996.tb02080.x Chang, 2011, Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo, Clincal Cancer Research, 17, 7116, 10.1158/1078-0432.CCR-11-0796 Chiarini, 2008, The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism, Leukemia, 22, 1106, 10.1038/leu.2008.79 Crul, 2002, Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours, European Journal of Cancer, 38, 1615, 10.1016/S0959-8049(02)00127-2 Dobson, 2001, Prognostic variables in canine multicentric lymphosarcoma, Journal of Small Animal Practice, 42, 377, 10.1111/j.1748-5827.2001.tb02485.x Garrett, 2002, Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma, Journal of Veterinary Internal Medicine, 16, 704, 10.1111/j.1939-1676.2002.tb02411.x Gromicho, 2011, Development of imatinib and dasatinib resistance. Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1, Leukemia and Lymphoma, 52, 1980, 10.3109/10428194.2011.584005 Hiraoka, 2009, Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines, Journal of Veterinary Medical Science, 71, 769, 10.1292/jvms.71.769 Keller, 1993, Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma, Journal of Veterinary Internal Medicine, 7, 289, 10.1111/j.1939-1676.1993.tb01021.x Lee, 1996, P-glycoprotein expression in canine lymphoma. A relevant, intermediate model of multidrug resistance, Cancer, 77, 1892, 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U Marconato, 2011, The staging and treatment of multicentric high-grade lymphoma in dogs. A review of recent developments and future prospects, The Veterinary Journal, 188, 34, 10.1016/j.tvjl.2010.04.027 Modok, 2006, Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer, Current Opinion in Pharmacology, 6, 350, 10.1016/j.coph.2006.01.009 Moore, 1995, The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance, Cancer Investigation, 13, 475, 10.3109/07357909509024910 Moore, 2001, Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma, Journal of Veterinary Internal Medicine, 15, 348, 10.1111/j.1939-1676.2001.tb02328.x Nakaichi, 1996, Establishment and characterization of a new canine B-cell leukemia cell line, Journal of Veterinary Medical Science, 58, 469, 10.1292/jvms.58.469 O'Connor, 2007, The pharmacology of cancer resistance, Anticancer Research, 27, 1267 Rutgen, 2010, Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma, Leukemia Research, 34, 932, 10.1016/j.leukres.2010.01.021 Schmidt-Hieber, 2012, In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines, Investigational New Drugs, 30, 480, 10.1007/s10637-010-9576-2 Skolnik, 2006, A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer, Cancer Chemotherapy and Pharmacology, 57, 458, 10.1007/s00280-005-0065-9 Srivastava, 2013, Perifosine in renal cell carcinoma, Expert Opinion on Investigational Drugs, 22, 285, 10.1517/13543784.2013.754422 Tomiyasu, 2010, Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma, Journal of Veterinary Medical Science, 72, 1165, 10.1292/jvms.09-0575 Tomiyasu, 2013, Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines, Leukemia and Lymphoma, 54, 1309, 10.3109/10428194.2012.751529 Tomiyasu, 2013, Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients, The Veterinary Journal, 199, 103, 10.1016/j.tvjl.2013.10.022 van Blitterswijk, 2013, Anticancer mechanisms and clinical application of alkylphospholipids, Biochimica et Biophysica Acta, 1831, 663, 10.1016/j.bbalip.2012.10.008 Yamazaki, 2008, Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction, Veterinary Immunology and Immunopathology, 126, 321, 10.1016/j.vetimm.2008.09.004 Zhu, 2012, Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer, PLoS ONE, 7, e41763, 10.1371/journal.pone.0041763